# Asthma and Allergic Diseases Group

> **NIH NIH UM2** · RHO FEDERAL SYSTEMS DIVISION, INC. · 2021 · $2,779,939

## Abstract

PROJECT SUMMARY/ABSTRACT—ASTHMA AND ALLERGIC DISEASES GROUP 
 Through this Funding Opportunity Announcement, the NIAID Division of Allergy, Immunology and 
Transplantation (DAIT) intends to consolidate its funding for multiple, independent Statistical and Clinical 
Coordinating Centers (SACCCs) into a single multi-component cooperative agreement, presumably to reduce 
costs and increase efficiency and standardization across research consortia. This new program will fund a 
single SACCC or Center to support DAIT research in the areas of asthma and allergic diseases, autoimmune 
diseases, and transplantation, and in the area of asthma and allergic diseases research, this Center will 
provide support to 5 consortia—the Asthma and Allergic Diseases Cooperative Research Centers (AADCRCs), 
the Atopic Dermatitis Research Network (ADRN), the Consortium of Food Allergy Research (CoFAR), the 
Inner-City Asthma Consortium (ICAC), and the asthma and allergy component of Immune Tolerance Network 
(ITN). Within the Center, support for these 5 consortia will be organized under 1 group—the Asthma and 
Allergy Diseases Group (AADG). The objective of the AADG is to provide excellent and efficient study 
coordination support services across the 5 asthma and allergic diseases research consortia. To accomplish 
this objective, RhoFED aims to (1) provide staff experienced in asthma and allergic disease research 
conducted by DAIT-supported consortia and to organize these staff in an administrative structure that manages 
resources efficiently, is responsive to the needs of the research consortia and DAIT, and facilitates 
communication and collaboration; (2) provide experienced scientists and statisticians who, in collaboration with 
clinical investigators and senior DAIT officials, design and analyze studies across the full scope of research in 
asthma and allergic diseases; (3) facilitate the development, review, and revision of initial and successive 
drafts of protocols and protocol-related documents through dedicated AADG protocol teams; and (4) provide 
study initiation and study management functions that are required for the efficient, valid, and ethical conduct of 
studies. In addition, the AADG will support the continuation of the ADRN Subject Registry and the ICAC 
Clinical Specimen Repository. Because RhoFED is currently the SACCC for ADRN, ICAC, and ITN and 
maintains the ADRN Subject Registry and the ICAC Clinical Specimen Repository, RhoFED is well suited to 
provide consolidated SACCC support across the 5 consortia. And, by providing staff with experience in 
supporting asthma and allergic disease research consortia and an administrative infrastructure designed to 
enhance collaboration between parties and support agile and effective resource management, we believe that 
support of these 5 consortia through the newly formed Center and the AADG will directly contribute to the 
achievement of the DAIT objective to better understand, treat, and prevent as...

## Key facts

- **NIH application ID:** 10150752
- **Project number:** 5UM2AI117870-07
- **Recipient organization:** RHO FEDERAL SYSTEMS DIVISION, INC.
- **Principal Investigator:** Samuel Arbes
- **Activity code:** UM2 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $2,779,939
- **Award type:** 5
- **Project period:** 2015-05-07 → 2022-04-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10150752

## Citation

> US National Institutes of Health, RePORTER application 10150752, Asthma and Allergic Diseases Group (5UM2AI117870-07). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10150752. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*